{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:18Z","timestamp":1792103838149,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The coexistence of HBV infection and hepatic steatosis is a novel characteristic of liver disease. Silibinin capsules (SC) is a silybin-phospholipid complex containing silybin as the bioactive component, which exerts a remarkable biological effect on various liver diseases, including nonalcoholic fatty liver disease (NAFLD). The purpose of this study was to investigate (1) the prevalence of hepatic steatosis in the general population and patients with chronic hepatitis B (CHB) and (2) to evaluate the effect of SC combined with therapeutic lifestyle changes (TLC) compared with TLC alone on hepatic steatosis in patients with CHB. A total of 16,451 individuals underwent transient elastography (TE) with the control attenuation parameter (CAP) measurement, among which the prevalence of hepatic steatosis was 31.1% in patients with CHB and 42.2% in the general population. The prevalence of hepatic steatosis differed between patients with CHB and the general population at an age of 40\u00a0years or older but was similar in individuals aged 39\u00a0years or younger (p\u2009&lt;\u20090.05). Furthermore, in patients with CHB presenting hepatic steatosis, the post-6-month relative reduction in CAP in the SC combined with TLC group (p\u2009=\u20090.001) was significantly greater than in the TLC alone group (p\u2009=\u20090.183). The CAP distribution of different steatosis grades (S1, S2, and S3) in the SC combined with TLC group was decreased and S0 (CAP\u2009&lt;\u2009248\u00a0dB\/m) increased significantly, but not significant in the TLC group. Thus, SC combined with TLC may effectively improve hepatic steatosis in patients with CHB.<\/jats:p>","DOI":"10.1038\/s41598-020-80709-z","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T14:24:12Z","timestamp":1610461452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B"],"prefix":"10.1038","volume":"11","author":[{"given":"Duo-Duo","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"80709_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol. Int. 10, 1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4 (2016).","journal-title":"Hepatol. Int."},{"key":"80709_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.dld.2009.01.004","volume":"41","author":"S Petta","year":"2009","unstructured":"Petta, S., Muratore, C. & Craxi, A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digest. Liver Dis. 41, 615\u2013625. https:\/\/doi.org\/10.1016\/j.dld.2009.01.004 (2009).","journal-title":"Digest. Liver Dis."},{"key":"80709_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MEG.0b013e328326792e","volume":"21","author":"M Minakari","year":"2009","unstructured":"Minakari, M. et al. Liver steatosis in patients with chronic hepatitis B infection: Host and viral risk factors. Eur. J. Gastroenterol. Hepatol. 21, 512\u2013516. https:\/\/doi.org\/10.1097\/MEG.0b013e328326792e (2009).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"80709_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/1756283X16681707","volume":"10","author":"H Ou","year":"2017","unstructured":"Ou, H., Cai, S., Liu, Y., Xia, M. & Peng, J. A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therap. Adv. Gastroenterol. 10, 207\u2013217. https:\/\/doi.org\/10.1177\/1756283X16681707 (2017).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"80709_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14218\/JCTH.2017.00013","volume":"5","author":"JM Pappachan","year":"2017","unstructured":"Pappachan, J. M., Babu, S., Krishnan, B. & Ravindran, N. C. Non-alcoholic fatty liver disease: A clinical update. J. Clin. Transl. Hepatol. 5, 384\u2013393. https:\/\/doi.org\/10.14218\/JCTH.2017.00013 (2017).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"80709_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","volume":"58","author":"M Blachier","year":"2013","unstructured":"Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D. C. & Roudot-Thoraval, F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 58, 593\u2013608. https:\/\/doi.org\/10.1016\/j.jhep.2012.12.005 (2013).","journal-title":"J. Hepatol."},{"key":"80709_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.15403\/jgld.2014.1121.smu","volume":"24","author":"S Mueller","year":"2015","unstructured":"Mueller, S. CAP: A novel era to better quantitate fatty liver?. JGLD 24, 11\u201313. https:\/\/doi.org\/10.15403\/jgld.2014.1121.smu (2015).","journal-title":"JGLD"},{"key":"80709_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022\u20131030. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022 (2017).","journal-title":"J. Hepatol."},{"key":"80709_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa, P. & Carrat, F. Liver biopsy: The best, not the gold standard. J. Hepatol. 50, 1\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2008.10.014 (2009).","journal-title":"J. Hepatol."},{"key":"80709_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Castera","year":"2005","unstructured":"Castera, L. et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343\u2013350 (2005).","journal-title":"Gastroenterology"},{"key":"80709_CR11","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","volume":"22","author":"I Mikolasevic","year":"2016","unstructured":"Mikolasevic, I. et al. Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease: Where do we stand?. World J. Gastroenterol. 22, 7236\u20137251. https:\/\/doi.org\/10.3748\/wjg.v22.i32.7236 (2016).","journal-title":"World J. Gastroenterol."},{"key":"80709_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","volume":"65","author":"Y Fazel","year":"2016","unstructured":"Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D. & Younossi, Z. M. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 65, 1017\u20131025. https:\/\/doi.org\/10.1016\/j.metabol.2016.01.012 (2016).","journal-title":"Metabolism"},{"key":"80709_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms17050774","volume":"17","author":"L Calzadilla Bertot","year":"2016","unstructured":"Calzadilla Bertot, L. & Adams, L. A. The natural course of non-alcoholic fatty liver disease. Int. J. Mol. Sci. 17, 1. https:\/\/doi.org\/10.3390\/ijms17050774 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"80709_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","volume":"93","author":"K Flora","year":"1998","unstructured":"Flora, K., Hahn, M., Rosen, H. & Benner, K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 93, 139\u2013143. https:\/\/doi.org\/10.1111\/j.1572-0241.1998.00139.x (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"80709_CR15","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","volume":"15","author":"C Wah Kheong","year":"2017","unstructured":"Wah Kheong, C., Nik Mustapha, N. R. & Mahadeva, S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 15, 1940\u20131949. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.016 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"80709_CR16","doi-asserted-by":"publisher","first-page":"8742075","DOI":"10.1155\/2019\/8742075","volume":"2019","author":"A Federico","year":"2019","unstructured":"Federico, A. et al. Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients. Oxid. Med. Cell. Long. 2019, 8742075. https:\/\/doi.org\/10.1155\/2019\/8742075 (2019).","journal-title":"Oxid. Med. Cell. Long."},{"key":"80709_CR17","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3748\/wjg.v17.i18.2288","volume":"17","author":"C Loguercio","year":"2011","unstructured":"Loguercio, C. & Festi, D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 17, 2288\u20132301. https:\/\/doi.org\/10.3748\/wjg.v17.i18.2288 (2011).","journal-title":"World J Gastroenterol"},{"key":"80709_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/1414-431x20122551","volume":"46","author":"J Yao","year":"2013","unstructured":"Yao, J. et al. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz. J. Med. Biol. Res. 46, 270\u2013277. https:\/\/doi.org\/10.1590\/1414-431x20122551 (2013).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"80709_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.dld.2005.05.011","volume":"37","author":"A Di Sario","year":"2005","unstructured":"Di Sario, A. et al. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Digest. Liver Dis. 37, 869\u2013876. https:\/\/doi.org\/10.1016\/j.dld.2005.05.011 (2005).","journal-title":"Digest. Liver Dis."},{"key":"80709_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","volume":"50","author":"JG Fan","year":"2009","unstructured":"Fan, J. G. & Farrell, G. C. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 50, 204\u2013210. https:\/\/doi.org\/10.1016\/j.jhep.2008.10.010 (2009).","journal-title":"J. Hepatol."},{"key":"80709_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VW Wong","year":"2012","unstructured":"Wong, V. W. et al. Hepatitis B virus infection and fatty liver in the general population. J. Hepatol. 56, 533\u2013540. https:\/\/doi.org\/10.1016\/j.jhep.2011.09.013 (2012).","journal-title":"J. Hepatol."},{"key":"80709_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso, M. et al. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 36, 1825\u20131835. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2010.07.005 (2010).","journal-title":"Ultrasound Med. Biol."},{"key":"80709_CR23","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1111\/liv.12305","volume":"34","author":"S Carvalhana","year":"2014","unstructured":"Carvalhana, S., Leitao, J., Alves, A. C., Bourbon, M. & Cortez-Pinto, H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: Correlation with ultrasound. Liver Int. 34, E111\u2013E117. https:\/\/doi.org\/10.1111\/liv.12305 (2014).","journal-title":"Liver Int."},{"key":"80709_CR24","doi-asserted-by":"publisher","unstructured":"Tasneem, A. A., Luck, N. H. & Majid, Z. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Trop. Doct. 49475517742261. https:\/\/doi.org\/10.1177\/0049475517742261 (2017).","DOI":"10.1177\/0049475517742261"},{"key":"80709_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jdiacomp.2018.05.008","volume":"32","author":"PJ Patel","year":"2018","unstructured":"Patel, P. J. et al. Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. J. Diabetes Compl. 32, 799\u2013804. https:\/\/doi.org\/10.1016\/j.jdiacomp.2018.05.008 (2018).","journal-title":"J. Diabetes Compl."},{"key":"80709_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/jrms.JRMS_711_16","volume":"22","author":"Z Saremi","year":"2017","unstructured":"Saremi, Z., Rastgoo, M., Mohammadifard, M., Bijari, B. & Akbari, E. Comparison of platelet number and function between nonalcoholic fatty liver disease and normal individuals. J. Res. Med. Sci. 22, 75. https:\/\/doi.org\/10.4103\/jrms.JRMS_711_16 (2017).","journal-title":"J. Res. Med. Sci."},{"key":"80709_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/GME.0000000000000647","volume":"23","author":"RE Rezende","year":"2016","unstructured":"Rezende, R. E. et al. Randomized clinical trial: Benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. Menopause 23, 876\u2013883. https:\/\/doi.org\/10.1097\/GME.0000000000000647 (2016).","journal-title":"Menopause"},{"key":"80709_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","volume":"50","author":"M Trappoliere","year":"2009","unstructured":"Trappoliere, M. et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J. Hepatol. 50, 1102\u20131111. https:\/\/doi.org\/10.1016\/j.jhep.2009.02.023 (2009).","journal-title":"J. Hepatol."},{"key":"80709_CR29","doi-asserted-by":"publisher","first-page":"e9061","DOI":"10.1097\/MD.0000000000009061","volume":"96","author":"S Zhong","year":"2017","unstructured":"Zhong, S. et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine 96, e9061. https:\/\/doi.org\/10.1097\/MD.0000000000009061 (2017).","journal-title":"Medicine"},{"key":"80709_CR30","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","volume":"52","author":"C Loguercio","year":"2012","unstructured":"Loguercio, C. et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med. 52, 1658\u20131665. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.02.008 (2012).","journal-title":"Free Radic. Biol. Med."},{"key":"80709_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000453364","volume":"24","author":"P Andrade","year":"2017","unstructured":"Andrade, P. et al. Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease. GE Port. J. Gastroenterol. 24, 161\u2013168. https:\/\/doi.org\/10.1159\/000453364 (2017).","journal-title":"GE Port. J. Gastroenterol."},{"key":"80709_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1586\/erd.10.46","volume":"7","author":"V de Ledinghen","year":"2010","unstructured":"de Ledinghen, V. & Vergniol, J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev. Med. Dev. 7, 811\u2013823. https:\/\/doi.org\/10.1586\/erd.10.46 (2010).","journal-title":"Expert Rev. Med. Dev."},{"key":"80709_CR33","doi-asserted-by":"publisher","unstructured":"European Association for Study of, L. & Asociacion Latinoamericana para el Estudio del, H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63, 237\u2013264. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.006 (2015).","DOI":"10.1016\/j.jhep.2015.04.006"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80709-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:47:08Z","timestamp":1670014028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80709-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80709"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80709-z","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739361423.793582010","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"655"}}